GlassScriptPhysician profile
Robert F Naples
NPI 1275506545
$20,102.17
in general payments reported to CMS, 2019-2025
55 companies · $3,164 in 2025
The $3,164 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $2,004 · 2021: $2,789 · 2022: $2,506 · 2023: $4,214 · 2024: $3,218 · 2025: $3,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,803 · Travel and Lodging: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,803.44 |
| Travel and Lodging | $792.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,400.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,963.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,592.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,581.57 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $1,540.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $898.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $855.46 | 2021-2025 | |
| Intuitive Surgical, INC. | $792.54 | 2023 | Da Vinci Surgical System |
| Lilly USA, LLC | $699.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $566.98 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.76 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $466.33 | 2019-2023 | |
| Amarin Pharma, INC. | $449.13 | 2019-2022 | |
| Astellas Pharma US INC | $379.83 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.77 | 2019-2024 | Xifaxan, Trulance |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $326.13 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $275.54 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $267.01 | 2019-2023 | Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $247.76 | 2020-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $244.54 | 2019-2025 | Camzyos, Eliquis |
| Otsuka America Pharmaceutical, INC. | $235.25 | 2021-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $217.04 | 2022-2025 | Rexulti, Vyepti |
| Allergan, INC. | $215.84 | 2019-2020 | |
| Abbott Laboratories | $145.40 | 2019-2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $132.38 | 2019-2023 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $126.85 | 2022 | |
| Horizon Therapeutics Plc | $126.21 | 2022-2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $122.58 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $119.04 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $117.43 | 2024-2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $112.26 | 2021 | |
| Nestle Healthcare Nutrition INC. | $109.07 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $89.41 | 2019-2023 | Seglentis, Livalo |
| Sunovion Pharmaceuticals INC. | $69.73 | 2019 | |
| Xeris Pharmaceuticals, INC. | $64.97 | 2022-2023 | Gvoke Hypopen |
| Upsher-Smith Laboratories LLC | $59.40 | 2020-2021 | |
| Esperion Therapeutics, INC. | $56.08 | 2021-2022 | |
| Daiichi Sankyo INC. | $50.51 | 2020 | |
| Inspire Medical Systems, INC. | $48.20 | 2023-2025 | Inspire |
| Eisai INC. | $43.11 | 2020-2021 | |
| Mylan Specialty L.P. | $42.54 | 2023-2024 | Yupelri |
| Axsome Therapeutics, INC. | $38.34 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $38.21 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $36.74 | 2023 | Gemtesa |
| Aimmune Therapeutics, INC. | $36.43 | 2024-2025 | Zenpep |
| Genentech USA, INC. | $36.26 | 2019-2020 | |
| Sanofi Pasteur INC. | $35.60 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $27.98 | 2019-2022 | |
| Pulmonx Corporation | $27.52 | 2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.60 | 2025 | Caplyta |
| Shield Therapeutics INC | $20.25 | 2023 | Accrufer |
| Amneal Pharmaceuticals LLC | $16.63 | 2023 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $15.46 | 2022 | |
| Biogen, INC. | $13.84 | 2021 | |
| Seqirus USA INC | $13.64 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Naples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.